LIFE aTyr Pharma Inc.

0.38
-0.01  -4%
Previous Close 0.39
Open 0.39
Price To Book 0.59
Market Cap 17,200,632
Shares 45,868,351
Volume 321,287
Short Ratio
Av. Daily Volume 462,682

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 patient trial to be initiated 4Q 2018.
ATYR1923
Pulmonary sarcoidosis

Latest News

  1. Edited Transcript of LIFE earnings conference call or presentation 13-May-19 9:00pm GMT
  2. Atyr Pharma: 1Q Earnings Snapshot
  3. aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
  4. aTyr Pharma to Announce First Quarter 2019 Results on May 13th
  5. aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
  6. aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
  7. Edited Transcript of LIFE earnings conference call or presentation 25-Mar-19 9:00pm GMT
  8. aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
  9. Atyr Pharma (LIFE) Upgraded to Buy: Here's Why
  10. aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
  11. aTyr Pharma, Inc. to Host Earnings Call
  12. aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  13. aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
  14. aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
  15. aTyr Pharma Announces Participation at March Investor Conferences
  16. aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
  17. Evolve Announces February 2019 Distributions for Evolve ETFs
  18. aTyr Pharma to Present at the BIO CEO & Investor Conference
  19. aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study